🇺🇸

US SEC Filing Intelligence

· daily

US Material Events SEC 8-K Filings — August 05, 2026

The 50 filings reveal a dynamic market with significant M&A, capital raises, and leadership transitions. Key themes include a surge in SPAC activity (McKinley, East West Ave, Charlton Aria, SilverBox), strategic divestitures (Gran Tierra, CoreCivic, Medalist), and transformative partnerships (Netlist-Samsung, Blue Bird-Ford). Financial performance is mixed: some companies show strong growth (Arcutis, Emergent, Zillow), while others face headwinds (Criteo, Honeywell, FTC Solar). Insider activity is limited, but notable CEO transitions at Flutter and CDW signal potential strategic shifts. Guidance changes are mixed, with raises at Arcutis and cuts at Honeywell and Criteo. Capital allocation trends include share repurchases (HF Sinclair, Criteo) and debt refinancing (PowerCompute, Bally's). Overall, the market is characterized by strategic repositioning and selective growth, with a cautious outlook in some sectors.

50 high priority 50 total filings
· daily

Insider Trading Pulse — August 05, 2026

The August 5, 2026, insider trading pulse reveals a day of starkly contrasting signals, dominated by significant insider selling at Cactus, Inc. and a massive vote of confidence from CoStar Group's founder. While the majority of filings involve routine equity awards and small, often plan-driven, transactions, two high-conviction events stand out: a $2.49M open-market purchase by CoStar's CEO and a combined ~$8.8M sell-off by Cactus's top executives. The data also shows a cluster of insider selling at biotech firms (Nurix, Korro Bio) and a notable sale by Mohawk Industries' largest shareholder. A significant portion of filings are non-actionable, consisting of beneficial ownership reports from MFS trust directors and a single unparseable filing. The key takeaway for investors is a bifurcated market where deep insider conviction in select growth stories (CoStar) contrasts sharply with profit-taking or risk-off positioning in cyclical and high-growth sectors (Energy, Biotech). No period-over-period comparisons or forward-looking guidance were present in the enriched data for this specific filing set, limiting trend analysis to transaction-level patterns.

50 high priority 50 total filings
· daily

Dow Jones 30 Stocks SEC Filings — August 05, 2026

The filings present a mixed but generally constructive Dow blue-chip picture: Caterpillar and Amgen delivered the strongest operating momentum, while Disney and Honeywell Aerospace exposed meaningful execution and guidance risks. Caterpillar's six-month sales and revenues rose 23.2% YoY and profit increased 46.9%, materially outpacing Amgen's still-strong 9.5% revenue growth and 65.9% net-income growth. Disney grew segment revenue 6.8% and total segment operating income 21% in Q3, but reported net income fell 52% and Sports operating income declined 17.3%, highlighting uneven earnings quality. Honeywell Aerospace's post-spin profile is the most important negative development: Q2 sales grew 5%, but net income dropped 70%, adjusted EBIT fell 7%, and full-year organic-growth and EBIT guidance were cut sharply. Insider activity is mixed, with Amazon and Microsoft executives reporting sales, Chevron director John Hess selling approximately $52.9 million of stock, and Honeywell Aerospace granting broad post-spin equity awards rather than reporting insider sales. Capital allocation remains supportive at Disney, which raised its 2026 buyback target to at least $9 billion, while American Express is refinancing or potentially redeeming preferred capital through a proposed Series E offering. Investors should prioritize the Honeywell guidance reset, Disney's Sports and advertising trends, Caterpillar Financial's rising credit stress, and upcoming clarification of management changes at Salesforce.

29 high priority 3 medium 32 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — August 05, 2026

On August 5, 2026, four US-listed companies filed 8-Ks disclosing critical corporate distress signals, with three facing imminent or potential delisting and one narrowly avoiding it. The filings reveal a severe liquidity and market access crisis in the small-cap biotech and software sectors, with Vistagen Therapeutics and Destination XL Group both confirming actual delistings due to failed continued listing standards, while Upland Software received a 180-day cure period for failing the $15M minimum market value of publicly held shares requirement. Genprex, Inc. represents a temporary reprieve, having regained Nasdaq compliance but under strict conditions requiring daily maintenance of a $1.00 bid price through December 7, 2026. The aggregate pattern shows zero insider buying across all four filings, no forward-looking guidance, and no capital allocation actions (dividends, buybacks), indicating management teams are in survival mode rather than growth mode. The concentration of distress events on a single filing date suggests potential systemic stress in micro-cap listings, with all four companies sharing characteristics of low market capitalization, negative sentiment, and high materiality scores (8-9/10).

4 high priority 4 total filings
· daily

Global High-Priority Regulatory Events — August 05, 2026

This digest covers 46 filings from August 5, 2026, with a heavy concentration on Indian-market M&A, insolvencies, and SPAC activity. The most critical development is the definitive business combination between McKinley Acquisition Corp. and Space-Eyes, Inc., implying a $638M valuation for the AI-driven geospatial intelligence firm, backed by a $75M PIPE and Eric Trump's involvement as an investor. Delisting and compliance risks are elevated for Destination XL Group, Vistagen Therapeutics, and Upland Software, while Genprex narrowly avoided delisting with strict conditions. A wave of Indian corporate insolvencies (Future Enterprises, Tricom Fruit Products, JCT Ltd) and related-party M&A (Tipco Engineering, Nahar Industrial) signals ongoing stress in smaller Indian industrials. On the positive side, CoreCivic generated $522.5M net proceeds from facility sales to DHS, and Palomino Laboratories completed a transformative acquisition of Vega Links, expanding its addressable market 10x to $60B. Period-over-period trends show mixed results: Sterling Tools grew revenue 23.8% YoY but declined 2.9% QoQ, while NCR Voyix saw a 21% YoY revenue decline due to its hardware transition. Capital allocation is defensive, with Medalist Diversified REIT selling assets to repay debt and TPG Twin Brook executing a 5% share buyback.

46 high priority 46 total filings
· daily

US SEC Filings Daily Market Digest — August 05, 2026

Today's digest (August 5, 2026) reveals a market bifurcated between strong top-line growth and mounting operational pressures. Revenue growth is a common theme, with 8 out of 10 reporting companies showing YoY increases, but margin compression and rising costs are eroding profitability for many. A notable pattern is the prevalence of 'mixed' sentiment (12 of 18 filings with sentiment data), driven by non-recurring gains masking underlying operational challenges, as seen in ZipRecruiter, Schrodinger, and Honest Company. Capital allocation is aggressive, with significant M&A activity (Labcorp, Warner Music, Blue Bird) and share buybacks (Uber, ZipRecruiter), but this is straining balance sheets, as evidenced by declining cash positions at Labcorp and Iron Mountain. Insider activity is limited, but the Space-Eyes SPAC merger with Eric Trump's involvement is a high-profile event. The most critical developments include Verra Mobility's downward guidance revision, LegalZoom's workforce reduction and lowered outlook, and the transformative CRH acquisition of Arcosa, which collectively signal caution in specific end-markets despite overall economic resilience.

23 high priority 27 medium 50 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — August 05, 2026

The 14 filings for the S&P 500 Consumer Discretionary stream reveal a sector bifurcated between strong operational execution and rising financial risks. eBay delivered a standout quarter with 15% YoY revenue growth and a 51% surge in net income, while raising full-year guidance, though Q3 guidance signals a deceleration. Yum Brands posted robust 12.2% revenue growth, but this was overshadowed by a massive 7,303% spike in short-term borrowings and a reliance on a one-time $320M tax benefit for earnings growth. Insider activity is a key negative signal: Amazon's Jeff Bezos sold $346M in stock, and two DoorDash directors collectively sold over $10M in shares near $200, all under 10b5-1 plans. Meanwhile, Chipotle faces a supply-chain salmonella scare, and Nike's executives engaged in routine tax-related stock withholding, offering no directional signal. The overarching theme is one of consumer resilience driving top-line growth, but with increasing leverage, insider profit-taking, and operational risks that warrant caution.

11 high priority 3 medium 14 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — August 05, 2026

The S&P 500 Healthcare sector is experiencing a bifurcated growth story, with GLP-1 leaders Eli Lilly and Amgen driving strong revenue expansion, while CVS Health shows a dramatic earnings recovery from a low base. Eli Lilly's Q2 2026 revenue surged 48% YoY, driven by Mounjaro and Zepbound, but EPS growth was significantly tempered by $3.03 per share in acquired IPR&D charges, creating a mixed signal. Amgen posted a 9.5% revenue increase and a 65.9% net income surge, benefiting from cost discipline. CVS Health raised full-year guidance after a 191.8% net income jump, though medical membership declined by 0.7 million. The most striking insider signal comes from Boston Scientific, where the CEO made a $9M open-market purchase, indicating strong conviction. AbbVie's 8-K filing was purely informational with no material data. Overall, the sector shows robust top-line growth but with rising R&D spending and regulatory headwinds from the IRA.

5 high priority 3 medium 8 total filings
· daily

US Executive Compensation Proxy SEC Filings — August 05, 2026

The six DEF 14A filings for the 2026 proxy season reveal a period of significant corporate transition and governance evolution. The most critical development is the pending all-stock merger of Corebridge Financial with Equitable Holdings, which will reshape the financial services landscape and marks the company's final annual meeting. Saratoga Investment Corp. presents a stable, routine governance profile with a standard director election and auditor ratification. The remaining four filings—Capital Management Investment Trust, Cardio Diagnostics Holdings, Bowhead Specialty Holdings, and Northern Lights Fund Trust III—are classified as medium risk with moderate materiality, suggesting standard governance practices without major compensation or shareholder proposal controversies. Period-over-period comparisons are limited across the set, but the Corebridge merger creates a clear catalyst for valuation convergence. Insider activity is not explicitly flagged in the enriched data, but the merger approval by both boards and stockholders signals strong management alignment. The overall theme is one of structural change in financial services, with a focus on shareholder value realization through M&A, while other filings indicate a stable, low-event proxy season for smaller entities.

6 high priority 6 total filings
· daily

US IPO Pipeline SEC S-1 Filings — August 05, 2026

The IPO pipeline for August 5, 2026, is dominated by two SPAC filings (Gravity Acquisition Corp. and BNB PLUS CORP.) and a highly opaque business combination filing (Criteo Holdings, Inc.), signaling a cautious but active market for blank-check companies. No period-over-period comparisons, insider trading, capital allocation, or forward-looking guidance are available across any of the three filings, as the S-1 and S-4 registrations are initial or incomplete. Gravity Acquisition Corp. provides the most concrete data with a $252.7 million unit offering at $10.00, a 15-month deadline, and sponsor lock-up provisions, but lacks any operational metrics or financial trends. BNB PLUS CORP. and Criteo Holdings offer virtually no actionable financial or strategic details, resulting in high uncertainty and low materiality. The overarching theme is a lack of transparency typical of early-stage IPO filings, with no sector concentration or cross-cutting patterns to exploit. Investors should monitor these filings for subsequent amendments (S-1/A, 8-K) that will provide critical pricing, financial, and business combination details.

3 high priority 3 total filings
· daily

US SEC Trading Suspension Halt Orders — August 05, 2026

The August 5, 2026, trading suspension and delisting digest reveals a bifurcated micro-cap landscape: two companies (DXLG, VTGN) face imminent delisting with high/critical risk, one (UPLD) is on a 180-day watch for a market value deficiency, and one (GNPX) has narrowly regained compliance under strict conditions. No period-over-period financial trends, insider activity, or forward-looking guidance were disclosed in any of the filings, limiting quantitative trend analysis. The dominant theme is regulatory survival—companies are either in active remediation or facing terminal loss of exchange listing. The lack of insider transactions or capital allocation data across all four filings suggests these events are primarily driven by market price and liquidity crises rather than operational deterioration. The most actionable insight is the Genprex compliance extension, which creates a high-stakes monitoring window through December 7, 2026, while Upland's 180-day cure period offers a potential turnaround play if management executes a reverse split or buyback.

4 high priority 4 total filings
· daily

US Executive Officer Management Changes SEC — August 05, 2026

This digest of 37 SEC filings reveals a day of significant leadership transitions, with several high-profile CEO and CFO departures creating a mix of opportunity and uncertainty. Key themes include a wave of CFO changes at companies like Dynatrace, Criteo, GoodRx, and Chime Financial, often coinciding with mixed financial results and lowered guidance, signaling potential strategic pivots. Conversely, strong operational performance and strategic board appointments at companies like Target Hospitality and Symbotic point to growth-oriented governance. A notable risk cluster involves sudden, unexplained CEO departures at Transportation & Logistics Systems and BlockchAIn Digital Infrastructure, creating leadership vacuums. Overall, the market is seeing a bifurcation between well-planned successions at outperforming firms and abrupt exits at those facing headwinds, with the latter group demanding closer scrutiny. Period-over-period data highlights a trend of margin compression and lowered guidance at several firms, including Criteo and Honeywell Aerospace, despite revenue growth in some cases, suggesting rising costs or strategic investments are pressuring profitability. Insider activity, while not explicitly detailed in many filings, is inferred through the leadership changes themselves, with the departure of CFOs at underperforming companies being a potential bearish signal. Capital allocation trends show a mix of continued buybacks (Criteo) and new equity programs (Bed Bath & Beyond), indicating divergent financial strategies. Scheduled events, such as upcoming earnings calls and FDA decisions, provide a clear catalyst calendar for the coming weeks and months. The most critical developments are the CEO transition at Flutter Entertainment, which appears well-managed, and the sudden CEO exits at Transportation & Logistics Systems and BlockchAIn Digital Infrastructure, which are high-risk events. Portfolio-level patterns include a concentration of leadership changes in the tech and financial services sectors, with a notable number of CFO departures suggesting a broader trend of financial leadership turnover. The data also shows a clear divergence between companies with strong forward-looking guidance (e.g., Arcutis, Chime) and those cutting expectations (e.g., Criteo, Honeywell Aerospace), providing a clear framework for identifying outperformers and underperformers. The combination of leadership changes, financial performance, and forward-looking statements creates a rich set of actionable intelligence for investors.

37 high priority 37 total filings
· daily

US Corporate Board Director Changes SEC Filings — August 05, 2026

This digest of 37 SEC filings reveals a significant wave of leadership transitions across US public companies on August 5, 2026, with a notable concentration of CFO changes. The data shows a bifurcated market: high-growth companies like Dynatrace, Symbotic, and Arcutis are reporting strong operational metrics (ARR up 17%, revenue up 22%, net income swing to positive) while simultaneously managing executive departures, creating a nuanced risk/reward profile. Conversely, several filings signal distress, including a sudden CEO departure without a successor at Transportation & Logistics Systems and a widening net loss at Emergent BioSolutions despite revenue growth. A key portfolio-level trend is the prevalence of 'mixed' sentiment (8 out of 37 filings), where strong revenue growth is offset by margin compression, guidance cuts, or leadership instability. The data also highlights a strategic shift in board composition, with companies like Target Hospitality and Constellation Energy appointing directors with deep expertise in AI infrastructure and financial services, respectively, signaling a focus on future growth areas. Insider activity is limited in these filings, but the lack of disclosed reasons for several departures (e.g., Galaxy Digital, Aeva Technologies) raises governance flags. The forward-looking data provides a clear catalyst calendar, with key events including Dynatrace's CFO transition, Criteo's redomiciliation vote, and Arcutis's PDUFA date, offering actionable timelines for investors. Overall, the intelligence suggests a market in flux, where leadership changes are both a source of opportunity (new strategic direction) and risk (execution uncertainty), demanding careful scrutiny of each company's specific context and forward guidance.

37 high priority 37 total filings
· daily

US Merger & Acquisition SEC Filings — August 05, 2026

The August 5, 2026 filings reveal a highly active M&A landscape dominated by SPAC activity and strategic asset transactions. Key themes include a wave of SPAC IPOs (East West Ave, BOA Acquisition Corp II) raising $225M combined, and de-SPAC progress with McKinley Acquisition Corp announcing a $638M merger with Space-Eyes. Notable strategic M&A includes CoreCivic's $734M sale of two detention facilities to the DHS, and Palomino Laboratories' acquisition of Vega Links to expand into AI interconnects. Eton Pharmaceuticals licensed a promising late-stage dermatology product, while Medalist Diversified REIT executed a portfolio transformation through $76.6M in property dispositions. However, several SPACs (Charlton Aria, New America Acquisition I) show signs of distress with extended deadlines and director departures. NCR Voyix reported mixed Q2 results with revenue declining 21% YoY but recurring revenue growing, while maintaining full-year guidance. The overall sentiment is cautiously positive for active deal-making but with significant execution risks in the SPAC sector.

14 high priority 14 total filings
· monthly

US Pre-Market SEC Filings Roundup — August 05, 2026

The overnight SEC filings reveal a market bifurcated by AI-driven demand and geopolitical tailwinds versus margin compression and rising costs. Key themes include strong revenue growth in AI-related sectors (Vishay, Kennametal) and energy (Dorian LPG, Gran Tierra), contrasted with profitability challenges in consumer and healthcare (Verano, Edgewell, Capri). Guidance changes were mixed, with raises from Royalty Pharma, Elanco, and Primo Brands, but cuts from Flutter, Insulet, and LivaNova. Insider activity was limited, with notable sales at Nurix and Shell. Capital allocation trends show continued buybacks and dividends, though some companies reduced repurchases (Brink's). The most significant event is the imminent closing of Banco Santander's acquisition of Webster Financial, while Compass Pathways' Phase 3 data and NDA progress present a major catalyst. Overall, the data suggests selective opportunities in AI, energy, and pharma, while caution is warranted in consumer and high-leverage names.

19 high priority 31 medium 50 total filings
· daily

Biotech Small-Cap Approvals — August 04, 2026

The August 4, 2026 digest covers 6 FDA approvals, all classified as 'Other' (primarily biosimilar and one label expansion), with zero NMEs, biosimilars (as defined by the stream), or label expansions in the traditional sense. The dominant theme is generic/biosimilar competition in mature therapeutic areas, with approvals for ATROPINE SULFATE (GLAND), DOCOSANOL (KLM LABS PVT), ASCORBIC ACID (STIRA), FEXOFENADINE HYDROCHLORIDE (DR REDDYS), and DOFETILIDE (INNOGENIX INC). The highest-conviction signal is the label expansion for an unknown drug from HANDA ONCOLOGY, LLC, which is the only bullish signal in the period, suggesting potential for revenue growth in oncology. A key watch item is the lack of NME approvals, indicating a low-catalyst period for novel therapies, and the reliance on biosimilar entries which may pressure originator pricing.

6 total filings
· daily

Big Pharma Approvals — August 04, 2026

During the single-day period of August 04, 2026, the FDA issued only one approval event—a label expansion for Novartis’ lutetium-based radiopharmaceutical, LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN (PLUVICTO). There were zero NMEs, zero biosimilars, and zero other label expansions, making this an extremely thin period with a solitary bullish signal. The dominant theme is the continued expansion of Novartis’ radioligand therapy franchise, though the lack of commercial detail (peak sales, pricing, exclusivity) limits conviction. The key risk is the absence of any de novo or competitive catalysts, leaving the period effectively a non-event for most sector portfolios.

1 total filings
· daily

New Drug Approvals (Original) — August 04, 2026

This digest covers 6 FDA approvals from a single day (August 4, 2026), all classified as 'Other' (FALLBACK type), with zero NMEs, zero biosimilars, and zero label expansions. The dominant theme is generic/biosimilar approvals for established molecules, including ATROPINE SULFATE (GLAND), DOCOSANOL (KLM LABS PVT), ASCORBIC ACID (STIRA), FEXOFENADINE HYDROCHLORIDE (DR REDDYS), and DOFETILIDE (INNOGENIX INC). The only bullish signal is a label expansion for an undisclosed drug from HANDA ONCOLOGY, LLC, though the drug name is missing, limiting actionable insight. The lack of NME or high-value biosimilar approvals makes this a low-catalyst period for sector-wide investment moves; the key risk is the opacity around HANDA ONCOLOGY's expansion, which could be a significant oncology catalyst if disclosed.

6 total filings